Trials / Recruiting
RecruitingNCT06067100
U-LABA/ICS Effects on Exercise Performance, Indacaterol
Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Indacaterol
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Morten Hostrup, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indacaterol and Mometasonefluroate (low dose) | Participants are administered 125 µg indacaterol + mometasonefluroate |
| DRUG | Placebo | Participants are administered placebo |
| DRUG | Indacaterol and Mometasonefluroate (high dose) | Participants are administered 500 µg indacaterol + mometasonefluroate |
Timeline
- Start date
- 2024-01-15
- Primary completion
- 2026-07-15
- Completion
- 2026-12-01
- First posted
- 2023-10-04
- Last updated
- 2025-04-09
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT06067100. Inclusion in this directory is not an endorsement.